Enzyme SMYD3 play a role in prostate cancer progression: Research

WASHINGTON: According to the American Cancer Society, prostate cancer is the most frequent cancer in males after skin cancer, with over 288,000 new cases diagnosed each year.

Since the 1990s, the disease’s fatality rate has been reduced by more than half, but there is still space for improvement, particularly in treating or preventing advanced, metastatic disease, which is far more likely to be fatal.

A new study published in Science Advances explains how an enzyme called SMYD3 may play a role in the advancement of prostate cancer to a more hazardous and aggressive stage. The enzyme’s newly discovered function makes it a prime prospective therapeutic target for halting disease progression.

Researchers have been attempting to explain SMYD3’s role in cancer since observing that it is unusually abundant in cancerous tumors compared to healthy tissue, explains Erin Green, associate professor of biological sciences at University of Maryland, Baltimore County (UMBC) and senior author on the paper.

“There is a lot of interest in this protein,” Green says. “However,” she adds, “the literature has been muddled.”

Several previous studies suggested that SMYD3 acted inside a cell’s nucleus and regulated which genes the cell expressed by directly modifying DNA. But research led by Nicolas Reynoird, a scientist at the Institute for Advanced Biosciences in Grenoble, France and a co-author on the new study, suggested a different mechanism.

In a key 2014 paper published while Reynoird was a postdoctoral fellow at Stanford, he and collaborators found that SMYD3 was working outside the nucleus and activating a type of protein called a MAP kinase. MAP kinases are overactive in cancer cells and can promote tumor growth.

The new Science Advances paper, led by Sabeen Ikram, a postdoctoral fellow at Stanford University, built on Reynoird’s previous work. Ikram’s experiments showed conclusively and in detail how SMYD3 may be triggering metastatic prostate cancer via the MAP kinase signaling pathway. The new paper ties together overabundance of SMYD3 and excessive activation of MAP kinase signaling for the first time in prostate cancer, renewing interest in SMYD3 as a therapeutic target.

The research team showed in cells in a petri dish and in mice that adding methyl groups (a carbon atom bound to three hydrogen atoms) to the MAP kinase is probably SMYD3’s role in driving metastasis. Experiments with inactivated SMYD3 were much less likely to lead to metastasis.

Compounds that can inactivate SMYD3, called inhibitors, are already available, Green says. Ikram ran experiments with one of these, and found that it effectively killed cancer cells in a petri dish. The team would like to run the same experiments in mice to further confirm the compound’s effect. They’d also like to explore whether targeting SMYD3 could help tackle cancers that develop resistance to other treatments.

Ikram’s experiments also found that SMYD3 led to increased activity of a protein called vimentin, which is well-studied as a marker of cancer progression. Interestingly, SMYD3’s effect was specific to vimentin, even though it is a member of a large group of similar proteins.

Finally, the new study found for the first time that SMYD3 creates a positive feedback loop in the cell, where high levels of SMYD3 contribute to maintaining its overabundance.

Green sees many avenues for future work.

“We’ve only checked this mechanism in prostate cancer so far, but I think it’s likely happening in other cancer cell types,” Green says. “That’s another thing that we want to keep investigating: How common is this?”

Green is also excited for SMYD3’s potential use as a therapeutic target for prostate or other cancers. SMYD3 inhibitors already exist, so the new findings may encourage companies to invest in discovering new uses for them.

“There’s drugs out there that haven’t been fully explored because people decided there was not a good target,” Green said. “So there’s a lot more that could be done there.”